Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Insomnia, Myalgia, Paraesthesia, Pruritus, Scab
Clinical narrative: skin discoloration; Redness; Swelling on hands and feet; Scaliness; Scabbing of skin; tingling throughout the body; diminished sense of touch; loss of sleep due to itchiness and pain.; Unusual taste; shooting pain / tingling throughout the body; Since my 2nd dose I had a severe flair up of eczema.; Itching; Flaky Skin/Dry skin; This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (Since my 2nd dose I had a severe flair up of eczema.), PRURITUS (Itching), DRY SKIN (Flaky Skin/Dry skin), SKIN DISCOLOURATION (skin discoloration) and ERYTHEMA (Redness) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016B21A and 013A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy to animal dander (Describe the Reaction: Hives), Dust allergy (Describe the Reaction: Hives), Hives, Hypertension (Maintaining Levels), High cholesterol (Maintaining Levels) and Asthma (Allergy Asthma). Concomitant products included LOSARTAN for Cholesterol, ATORVASTATIN and FENOFIBRATE (FENOFIBRATE (II)) for an unknown indication.   On 25-Feb-2021 at 3:45 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021 at 3:45 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Feb-2021, the patient experienced PRURITUS (Itching) and DRY SKIN (Flaky Skin/Dry skin). On an unknown date, the patient experienced ECZEMA (Since my 2nd dose I had a severe flair up of eczema.), SKIN DISCOLOURATION (skin discoloration), ERYTHEMA (Redness), SWELLING (Swelling on hands and feet), SKIN EXFOLIATION (Scaliness), SCAB (Scabbing of skin), PARAESTHESIA (tingling throughout the body), SENSORY LOSS (diminished sense of touch), INSOMNIA (loss of sleep due to itchiness and pain.), AGEUSIA (Unusual taste) and MYALGIA (shooting pain / tingling throughout the body). The patient was treated with HYDROCORTISONE on 26-May-2021 for Adverse event, at a dose of (Quantity:56.7 Days Supply:30); HYDROCORTISONE on 03-May-2021 for Adverse event, at a dose of (Quantity:56.7 Days Supply:30); CLOBETASOL PROPIONATE (CLOBETASOL 0.05%) on 26-May-2021 for Adverse event, at a dose of Quantity:45 Days Supply:20; CLOBETASOL PROPIONATE (CLOBETASOL 0.05%) on 03-May-2021 for Adverse event, at a dose of Quantity:45 Days Supply:30; METHYLPREDNISOLONE ACETATE (METHYLPREDNISOLONE [METHYLPREDNISOLONE ACETATE]) on 10-May-2021 for Adverse event, at a dose of 4 mg (Quantity:21 Days Supply:6); PREDNISONE on 26-Jun-2021 for Adverse event, at a dose of 20 mg (Quantity:19 Days Supply:14); PREDNISONE on 22-Jul-2021 for Adverse event, at a dose of 20 mg (Quantity:33 Days Supply:28); MUPIROCIN on 07-Aug-2021 for Adverse event, at a dose of Quantity:22 Days Supply:7; MUPIROCIN on 16-Jun-2021 for Adverse event, at a dose of Quantity:22 Days Supply:7; FLUOCINONIDE on 19-Jul-2021 for Adverse event, at a dose of Quantity:60 Days Supply:20; FLUOCINONIDE on 16-Jun-2021 for Adverse event, at a dose of Quantity:60 Days Supply:20; HYDROXYZINE HCL on 16-Jun-2021 for Adverse event, at a dose of Quantity:60 Days Supply:20; TRIAMCINOLONE on 22-Jul-2021 for Adverse event, at a dose of 0.1% (Quantity:454 Days Supply:30); TRIAMCINOLONE on 29-Jul-2021 for Adverse event, at a dose of 0.025% (Quantity:160 Days Supply:30); TRIAMCINOLONE on 19-Aug-2021 for Adverse event, at a dose of 0.1% (Quantity:454 Days Supply:30) and TRIAMCINOLONE on 25-Aug-2021 for Adverse event, at a dose of 0.025% (Quantity:80 Days Supply:30). At the time of the report, ECZEMA (Since my 2nd dose I had a severe flair up of eczema.) outcome was unknown and PRURITUS (Itching), DRY SKIN (Flaky Skin/Dry skin), SKIN DISCOLOURATION (skin discoloration), ERYTHEMA (Redness), SWELLING (Swelling on hands and feet), SKIN EXFOLIATION (Scaliness), SCAB (Scabbing of skin), PARAESTHESIA (tingling throughout the body), SENSORY LOSS (diminished sense of touch), INSOMNIA (loss of sleep due to itchiness and pain.), AGEUSIA (Unusual taste) and MYALGIA (shooting pain / tingling throughout the body) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Jun-2021, Biopsy: eczema (abnormal) Eczema Biopsy 1 at 11AM. On 22-Jul-2021, Biopsy: eczema (abnormal) Eczema Biopsy 2 & 3.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient took concomitant medications of Echinacea 22-MAR-2021 to 20-APR-2021 through orally 1/daily and Elderbery 22-MAR-2021 to 03-MAY-2021 through orally 1/daily,    Most recent FOLLOW-UP information incorporated above includes: On 03-Sep-2021: Reporter information, patient medical history, concomitant medications, treatment medications added, events added, outcome updated and narrative was update accordingly